Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Income from Continuing Operations of 63734000.0 for Q1 2026, up 2.22% on a QoQ basis from 62349000.0 in Q4 2025, and up 12.33% year-over-year from 56737000.0 in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 63734000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 12.33% year-over-year to 63734000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 230974000.0 (up 17.04% YoY) and the FY2025 annual result came in at 223977000.0, up 36.66% from the prior year.
- Income from Continuing Operations was 63734000.0 for Q1 2026 at Catalyst Pharmaceuticals, up from 62349000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 63734000.0 in Q1 2026 and bottomed at 30764000.0 in Q3 2023.
- A 5-year average of 34604941.18 and a median of 37762000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 235.24% — and 2024, when it soared 242.65%.
- Catalyst Pharmaceuticals' Income from Continuing Operations stood at 25471000.0 in 2022, then slumped by 33.1% to 17039000.0 in 2023, then jumped by 228.28% to 55936000.0 in 2024, then rose by 11.46% to 62349000.0 in 2025, then rose by 2.22% to 63734000.0 in 2026.
- Business Quant data shows CPRX's Income from Continuing Operations at 63734000.0 in Q1 2026, 62349000.0 in Q4 2025, and 52783000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 63.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.73 Mn |
| Dec 31, 2025 | 62.35 Mn |
| Sep 30, 2025 | 52.78 Mn |
| Jun 30, 2025 | 52.11 Mn |
| Mar 31, 2025 | 56.74 Mn |
| Dec 31, 2024 | 55.94 Mn |
| Sep 30, 2024 | 43.88 Mn |
| Jun 30, 2024 | 40.79 Mn |
| Mar 31, 2024 | 23.28 Mn |
| Dec 31, 2023 | 17.04 Mn |
| Sep 30, 2023 | -30.76 Mn |
| Jun 30, 2023 | 37.76 Mn |
| Mar 31, 2023 | 29.57 Mn |
| Dec 31, 2022 | 25.47 Mn |
| Sep 30, 2022 | 22.75 Mn |
| Jun 30, 2022 | 21.62 Mn |
| Mar 31, 2022 | 13.24 Mn |
| Dec 31, 2021 | 9.31 Mn |
| Sep 30, 2021 | 10.33 Mn |
| Jun 30, 2021 | 12.18 Mn |